Status:
COMPLETED
Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab
Lead Sponsor:
Centre Francois Baclesse
Collaborating Sponsors:
University Hospital, Caen
Conditions:
Colon Cancer
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The main objective of this study is to validate the utility of IgE anti-cetuximab in the treatment strategy to identify patients at risk for a severe allergic reaction to cetuximab (grade 3 or 4 of th...
Eligibility Criteria
Inclusion
- Patient informed consent,
- Patient aged over 18 years
- Patients with a WHO performance status ≤ 2,
- Colon cancer or upper aero-digestive tract cytologically or histologically proven
- Patients with an indication to the theoretical use of cetuximab for colon neoplasia or upper aero-digestive tract,
- Haematological and biochemical compatible with combination therapy with cetuximab.
Exclusion
- Patients previously treated with cetuximab,
- A person deprived of liberty or under supervision.
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
303 Patients enrolled
Trial Details
Trial ID
NCT01436617
Start Date
January 1 2010
End Date
March 1 2013
Last Update
March 8 2013
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU
Amiens, France, 80054
2
Centre hospitalier
Bayeux, France, 14400
3
CHU
Caen, France, 14033
4
Centre François Baclesse
Caen, France, 14076